Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial.

Andrew B LassmanStephanie L PughTony J C WangKenneth D AldapeHui K GanMatthias PreusserMichael A VogelbaumErik P SulmanMinhee WonPeixin ZhangGolnaz MoazamiMarian S MacsaiMark R GilbertEarle E BainVincent BlotPeter J AnsellSuvajit SamantaMadan G KunduTerri S ArmstrongJeffrey S WefelClemens SeidelFilip Y de VosSigmund HsuAndrés F CardonaGiuseppe LombardiDmitry BentsionRichard A PetersonCraig GedyeVéronique BourgAntje WickWalter J CurranMinesh P Mehta

Published in: Neuro-oncology (2022)

Interim analysis demonstrated no OS benefit for depatux-m in treating EGFR-amp newly diagnosed GBM. No new important safety risks were identified.

Keyphrases

newly diagnosed
phase iii
small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
open label
double blind
clinical trial
placebo controlled
protein kinase
human health
randomized controlled trial
study protocol